About Xencor
Xencor is a biopharmaceutical company that specializes in the development of innovative medicines to treat patients with serious and life-threatening diseases. The company's mission is to improve patient outcomes by creating new therapies that target specific disease pathways.
One of Xencor's key strengths is its proprietary XmAb® technology platform, which enables the creation of highly targeted antibodies with enhanced therapeutic properties. This platform has been used to develop a number of promising drug candidates across a range of therapeutic areas, including oncology, autoimmune diseases, and allergic diseases.
In the field of oncology, Xencor has several drug candidates in clinical development that target different types of cancer. These include XmAb®14045, which targets CD123-expressing hematologic malignancies; XmAb®13676, which targets CD20-expressing B-cell malignancies; and XmAb®18087, which targets HER2-expressing solid tumors.
In autoimmune diseases, Xencor has developed several drug candidates that target specific immune pathways involved in disease pathogenesis. These include XmAb®5871, which targets CD19-expressing B cells in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA); and XmAb®7195, which targets IL-15 for the treatment of autoimmune disorders such as SLE and psoriasis.
Xencor also has a strong pipeline in allergic diseases. Its lead candidate in this area is XmAb®7195-OX40L, an antibody designed to block OX40L signaling for the treatment of asthma and other allergic conditions.
Overall, Xencor's innovative approach to drug development has led to a robust pipeline of potential therapies across multiple therapeutic areas. With its proprietary technology platform and experienced team of scientists and clinicians, Xencor is well-positioned to continue making significant contributions to the field of biopharmaceuticals for years to come.